Browsing Conditions by Subject "Alzheimer's Disease"
Now showing items 1-14 of 14
-
Adapted problem adaptation therapy for depression in mild to moderate Alzheimer's disease dementia: A randomized controlled trial
(2024-03)Introduction: Trials of effectiveness of treatment options for depression in dementia are an important priority. Methods: Randomized controlled trial to assess adapted Problem Adaptation Therapy (PATH) for depression in ... -
APOE genotype and cognition in healthy individuals at risk of Alzheimer's disease: A review
(2018-07)APOE-ε4 is best known as a risk factor for Alzheimer's disease (AD). Consequently, there is considerable research interest in understanding whether APOE-ε4 influences cognition in healthy adults. Despite a substantial ... -
Care needs of people with dementia in the peri-operative environment: A systematic review
(2018-11)The care of people with dementia within the hospital setting is challenging for healthcare professionals. Hospital design and services are not optimized for people with dementia, owing to the lack of preparation of healthcare ... -
CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice
(2019-08)Neuroinflammation and microglial activation are significant processes in Alzheimer’s disease pathology. Recent genome-wide association studies have highlighted multiple immune-related genes in association with Alzheimer’s ... -
Early- and subsequent- response of cognitive functioning in Alzheimer's disease: Individual-participant data from five pivotal randomized clinical trials of donepezil
(2022-02)The association between early improvement and subsequent change in cognition is unexamined in antidementia clinical trials. We aimed to examine the consequences of early-response to antidementia medication in Alzheimer's ... -
Ethics of Early Intervention in Alzheimer’s Disease
(2021-03)Alzheimer’s disease (AD) research, treatment, and prevention focus increasingly on developing personalized interventions based on personal genetic, biological, phenotypic data, for early intervention (EI) to limit harm. ... -
Health Outcome Prioritization in Alzheimer's Disease: Understanding the Ethical Landscape.
(2020-07)BACKGROUND:Dementia has been described as the greatest global health challenge in the 21st century on account of longevity gains increasing its incidence, escalating health and social care pressures. These pressures highlight ... -
Identification of Substrate-specific Allosteric Fingerprints in Matrix Metalloprotease-1 on Amyloid-beta Peptide Aggregates and Drug Screening With Single Molecule Insights
(2022-02)Amyloid-beta peptide (Aβ) is the primary component of water-insoluble extracellular plaques, one of the critical hallmarks of Alzheimer's disease (AD). Matrix metalloproteases (MMPs) are broad-spectrum proteases with ... -
Linking the Mini-Mental State Examination, the Alzheimer’s Disease Assessment Scale–Cognitive Subscale and the Severe Impairment Battery: evidence from individual participant data from five randomised clinical trials of donepezil
(2020-10)Background The Mini-Mental State Examination (MMSE), the Alzheimer’s Disease Assessment Scale–Cognitive Subscale (ADAS-Cog) and the Severe Impairment Battery (SIB) are widely used rating scales to assess cognition in ... -
Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease A Randomized Clinical Trial
(2019-11)IMPORTANCE There are no disease-modifying treatments for Alzheimer disease (AD), the most common cause of dementia. Minocycline is anti-inflammatory, protects against the toxic effects of β-amyloid in vitro and in animal ... -
Neurons derived from individual early Alzheimer’s disease patients reflect clinical vulnerability
(2021-11)Modelling sporadic Alzheimer’s disease (sAD) with patient-derived induced pluripotent stem cells (iPSCs) is challenging yet remains an important step in understanding the disease. Here we report a novel approach of sAD ... -
Quantification of allosteric communications in matrix metalloprotease-1 on alpha-synuclein aggregates and substratedependent virtual screening
(2021-01)Alpha-synuclein (aSyn) has implications in pathological protein aggregations observed in neurodegenerative disorders, including Parkinson's and Alzheimer's diseases. There are currently no approved prevention and cure ... -
Quantifying the heterogeneity of cognitive functioning in Alzheimer’s disease to extend the placebo-treatment dichotomy: Latent class analysis of individual-participant data from five pivotal randomized clinical trials of donepezil
(2021-02)Background. The extent and profiles of heterogeneity in cognitive functioning among participants in clinical trials of antidementia medication are unknown. We aimed to quantify and identify profiles of heterogeneity of ... -
Short-term memory advantage for brief durations in human APOE ε4 carriers
(2020-06)The Apolipoprotein-E (APOE) ε4 gene allele, the highest known genetic risk factor for Alzheimer’s disease, has paradoxically been well preserved in the human population. One possible explanation offered by evolutionary ...
